With regards to risks vis-a-vis benefits of ALK7 inhibition in therapeutic approaches to obesity, the fact that human carriers of ACVR1C variants were otherwise healthy is encouraging. Here, ACVR1C is linked to obesity due to melanocortin 4 receptor deficiency.